Brief: Tenaya Therapeutics Inc - FDA Places Clinical Hold On Tenaya's Mypeak-1 Trial - SEC Filing
07/11/2025 22:17
Tenaya Therapeutics Inc TNYA.O: TENAYA THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON TENAYA'S MYPEAK-1 TRIAL - SEC FILING TENAYA THERAPEUTICS INC - EXPECTS NO IMPACT ON TN-201 TIMELINES FROM HOLD - SEC FILING TENAYA THERAPEUTICS INC - FDA REQUESTS PROTOCOL AMENDMENT FOR TENAYA'S MYPEAK-1 TRIAL - SEC FILING TENAYA THERAPEUTICS INC - WORKING TO RESOLVE CLINICAL HOLD AND RESUME DOSING - SEC FILING Source text: [ID:n0001193125-25-272423] Further company coverage: TNYA.O
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027